Premium
[P2–407]: PREVALENCE OF AMYLOID‐PET POSITIVITY ACCORDING TO AGE AND APOE GENOTYPE IN PATIENTS WITH SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT
Author(s) -
San Lee Jin,
Kim Seonwoo,
Yoo Heejin,
Park Seongbeom,
Choe Yeongsim,
Jang Young Kyoung,
Ossenkoppele Rik,
Kim Hee Jin,
Kim Ko Woon,
Kim Yeshin,
Jang Hyemin,
Park KeyChung,
Weiner Michael,
Na Duk L.,
Seo Sang Won
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1062
Subject(s) - apolipoprotein e , amyloid (mycology) , genotype , medicine , cognitive impairment , allele , β amyloid , logistic regression , pathology , genetics , disease , alzheimer's disease , biology , gene
Background:Amnestic mild cognitive impairment (aMCI) refers to transitional state between normal aging and Alzheimer’s disease dementia. Previous studies suggested that there is a hierarchical order in aMCI. Especially, pathological studies revealed that aMCI had a variety of neurofibrillary Braak stages ranging 0 to VI. Recently, positron emission tomography (PET) tracers such as F-THK5351 ligand has been developed to detect tau deposition in-vivo. However, not much is known about the extent of in-vivo tau accumulation and its impact on cognition in aMCI patients. Therefore, we aimed to measure in-vivo Braak stage using FTHK5351 PET imaging. In addition, we evaluated the association between tau burden and cognition. Methods: We recruited 56 aMCI patients from Samsung Medical Center and Asan Medical Center. The presence of amyloid-ß was assessed by F-florbetaben PET. Paired helical filament tau was measured by F-THK5351 PET. Using conditional inference tree method, we classified each patient into in-vivo Braak stages based on mean THK5351 SUVR in the regions of anatomical Braak stages. Results: Of 56 aMCI patients, 6 (10.7%) were classified to in-vivo Braak stage 0, 6 (10.7%) to Braak stage I/II, 24 (42.9%) to Braak stage III/IV, and 20 (35.7%) to Braak stage V/VI. Among 31 amyloid positive aMCI patients, majority of patients were in Braak stage V/VI (45.2%), followed by Braak stage III/IV (38.7%), Braak stage I/II (10.7%) and Braak stage 0 (10.7%). However, among 25 amyloid negative aMCI patients, majority of patients were in Braak stage III/IV (48.0%), followed by Braak stage V/VI (24.0%), Braak stage I (16.0%), and Braak stage 0 (12.0%). THK5351 SUVR in limbic (Braak III/IV ROI) or isocortical (Braak V/VI ROI) area each correlated with visuospatial dysfunction; and THK5351 SUVR in entorhinal (Braak I/II ROI), limbic or isocortical area each correlated with visual memory impairment. Conclusions: We suggest that both amyloid positive and negative aMCI patients have various in-vivo Braak stages and that amyloid positive patients tend to be in higher Braak stages. Tau burden in limbic or isocortical areas was related to visuospatial and visual memory function.